awmsg logo



tedizolid phosphate (Sivextro®)


Reference No. 1607

Publication date:
10/12/2015


Appraisal information

tedizolid phosphate (Sivextro®) 200 mg film-coated tablet
tedizolid phosphate (Sivextro®) 200 mg powder for concentrate for solution for infusion


Company: Merck Sharp & Dohme Ltd
BNF category: Infections
NMG meeting date: 07/10/2015
AWMSG meeting date: 11/11/2015
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 3415
Ministerial ratification: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tedizolid phosphate (Sivextro®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with acute bacterial and skin structure infections (ABSSSI) caused by Gram-positive Staphylococcus aureus (specifically methicillin-resistant [MRSA] isolates) as an alternative oxazolidinione antibacterial. Treatment should only be initiated on advice from local microbiologists or specialists in infectious diseases. Tedizolid phosphate (Sivextro®) is not recommended for use within NHS Wales outside of this subpopulation/circumstance.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download